141 related articles for article (PubMed ID: 32373965)
1. MicroRNA-597 inhibits NSCLC progression through negatively regulating CDK2 expression.
Yu DJ; Li YH; Zhong M
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4288-4297. PubMed ID: 32373965
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-424-5p inhibits the development of non-small cell LCa by binding to ITGB1.
Xu ZL; Zhang M; Chen SX; Qiu M; Zhang Q; Gao LP; Li JDX
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8921-8930. PubMed ID: 31696479
[TBL] [Abstract][Full Text] [Related]
3. USP3 promotes proliferation of non-small cell lung cancer through regulating RBM4.
Liao XH; Wang Y; Zhong B; Zhu SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3143-3151. PubMed ID: 32271432
[TBL] [Abstract][Full Text] [Related]
4. MiRNA-488-3p inhibits malignant progression of NSCLC by modulating ADAM9.
Wu Y; Wu Y; Chen XY; Niu YX; Lv FZ; Gao W
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8893-8901. PubMed ID: 32964979
[TBL] [Abstract][Full Text] [Related]
5. LncRNA HOXA-AS2 regulates microRNA-216a-5p to promote malignant progression of non-small cell lung cancer.
Cui TJ; Lin GS; Dai YM; Zheng JP; Chen Z; Chen Q; Zheng Y; Lin X
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):264-273. PubMed ID: 31389597
[TBL] [Abstract][Full Text] [Related]
6. LncRNA TRERNA1 promotes malignant progression of NSCLC through targeting FOXL1.
Luo DB; Lv HB; Sun XH; Wang Y; Chu JH; Salai AL
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1233-1242. PubMed ID: 32096153
[TBL] [Abstract][Full Text] [Related]
7. CircRNA_MYLK promotes malignant progression of ovarian cancer through regulating microRNA-652.
Zhao Y; Hu Y; Shen Q; Chen Q; Zhu XJ; Jiang SS; Zhang Q
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5281-5291. PubMed ID: 32495861
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-198 inhibits metastasis of thyroid cancer by targeting H3F3A.
Fang J; Zhu JM; Dai HL; He LM; Kong L
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12232-12240. PubMed ID: 33336742
[TBL] [Abstract][Full Text] [Related]
9. Circ_0000064 adsorption of microRNA-143 promotes malignant progression of hepatocellular carcinoma.
Wu L; Xu XM; Li Y; Fan L
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9321-9330. PubMed ID: 31773699
[TBL] [Abstract][Full Text] [Related]
10. MiRNA-621 inhibits the malignant progression of non-small cell lung cancer via targeting SIX4.
Zhang M; Shi H; Zhang C; Zhang SQ
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4807-4814. PubMed ID: 31210312
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-548c-5p inhibits the proliferation of breast cancer cells through regulating Wnt/β-catenin signaling pathway.
He SZ; Wang Q
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3795-3804. PubMed ID: 32329856
[TBL] [Abstract][Full Text] [Related]
12. LncRNA WT-AS inhibits metastatic ability of non-small cell lung cancer by regulating KLK13.
Wang Y; Tan TZ; Wang LQ; Zhang K
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9429-9437. PubMed ID: 33015785
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of N-Acetylglucosaminyltransferase GCNT3 by miR-302b-3p Decreases Non-Small Cell Lung Cancer (NSCLC) Cell Proliferation, Migration and Invasion.
Li Q; Ran P; Zhang X; Guo X; Yuan Y; Dong T; Zhu B; Zheng S; Xiao C
Cell Physiol Biochem; 2018; 50(3):987-1004. PubMed ID: 30355927
[TBL] [Abstract][Full Text] [Related]
14. LncRNA SNHG14 promotes proliferation of endometrial cancer through regulating microRNA-655-3p.
Wang GF; Wen LN
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10410-10418. PubMed ID: 33155197
[TBL] [Abstract][Full Text] [Related]
15. LncRNA CRNDE promotes the development of Wilms' tumor by regulating microRNA-424.
Cui WW; Sun YL; Chen C; Feng RR; Xu W; Meng JJ; Zhang K
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1088-1097. PubMed ID: 32096178
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-19a promotes proliferative and migratory abilities of NSCLC cells by inhibiting PTEN expression.
Shi J; Han Y; Lin D; Wang K; Liu B; Gao C
J BUON; 2019; 24(3):955-962. PubMed ID: 31424647
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-9501 inhibits breast cancer proliferation and metastasis through regulating Wnt/β-catenin pathway.
Que LM; Yang XR; Zhang YC; Zhong H
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4337-4347. PubMed ID: 32373971
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of lncRNA FEZF1-AS1 in promoting the occurrence and development of oral squamous cell carcinoma through targeting miR-196a.
Xu L; Hou TJ; Yang P
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6505-6515. PubMed ID: 31378890
[TBL] [Abstract][Full Text] [Related]
19. LncRNA BX357664 inhibits the proliferation and invasion of non-small cell lung cancer cells.
Yang J; Du YM; Li B
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):660-669. PubMed ID: 30720174
[TBL] [Abstract][Full Text] [Related]
20. LncRNA DARS-AS1 regulates microRNA-129 to promote malignant progression of thyroid cancer.
Zheng W; Tian X; Cai L; Shen YM; Cao QS; Yang JY; Tian GY
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10443-10452. PubMed ID: 31841198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
